secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akili, Inc. (—)
CIK:        0001850266
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0001193125-24-123749
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akili cuts 46% of workforce, amends Shionogi deal for $10.5M upfront, explores strategic alternatives
--------------------------------------------------------------------------------

- Shionogi amendment provides $10.5M upfront payment, cancels $5M bond; Akili eligible for up to $7.5M in additional payments.
- Workforce reduced by 46%, eliminating marketing and medical affairs teams; severance costs estimated at $2.3-2.8M.
- Board initiates process to evaluate strategic alternatives, including a potential sale or other transaction.
- Q1 2024 financial results to be released May 14; no earnings conference call will be held.
- Akili will continue to support existing EndeavorRx and EndeavorOTC users and pursue FDA marketing authorization for EndeavorOTC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850266/000119312524123749/0001193125-24-123749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850266/000119312524123749/d830697d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-123749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer